Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 32586
Time Dependent Biodistribution Modeling of 177Lu-DOTATOC Using Compartmental Analysis

Authors: M. Mousavi-Daramoroudi, H. Yousefnia, F. Abbasi-Davani, S. Zolghadri


In this study, 177Lu-DOTATOC was prepared under optimized conditions (radiochemical purity: > 99%, radionuclidic purity: > 99%). The percentage of injected dose per gram (%ID/g) was calculated for organs up to 168 h post injection. Compartmental model was applied to mathematical description of the drug behaviour in tissue at different times. The biodistribution data showed the significant excretion of the radioactivity from the kidneys. The adrenal and pancreas, as major expression sites for somatostatin receptor (SSTR), had significant uptake. A pharmacokinetic model of 177Lu-DOTATOC was presented by compartmental analysis which demonstrates the behavior of the complex.

Keywords: Biodistribution, compartmental modeling, 177Lu, octreotide.

Digital Object Identifier (DOI):

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 673


[2] Virgolini, K. Britton, J. Buscombe, R. Moncayo, G. Paganelli and P. Riva, “In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.” Semin Nucl Med, Vol. 32, pp. 148-155, 2002.
[3] J. Kwekkeboom, J. J. Teunissen, W.H. Bakker, P. P .Kooij, W. W. de Herder, R. A. Feelders, C. H. van Eijck, J. P. Esser , B. L. Kam and E. P. Krenning, “Radiolabeled somatostatin analog (177Lu-DOTA0,Tyr3)octreotate in patients with endocrine gastroenteropancreatic tumors.” J Clin Oncol, Vol. 23, pp. 2745-2762, 2005.
[4] R. Valkema, S. Pauwels, L. K. Kvols, R. Barone, F. Jamar, W. H. Bakker, D. J. Kwekkeboom , H. Bouterfa and E. P. Krenning, “Survival and response after peptide receptor radionuclide therapy with (90Y-DOTA0)octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.” Semin Nucl Med, Vol. 36, pp. 147-156, 2006.
[5] J. Kwekkeboom, W. W. de Herder, B. L. Kam, C. H. van Eijck, M. van Essen, P.P. Kooij, R. A. Feelders , M. O. van Aken and E. P. Krenning , “Treatment with the radiolabeled somatostatin analog (177Lu-DOTA0, Tyr3)octreotate: toxicity, efficacy and survival.” J Clin Oncol, Vol 26, pp. 2124-2130, 2008.
[6] J. C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, J. E. Mares, E. K. Abdalla, J. B. Fleming, J. N. Vauthey, A. Rashid and D. B. Evans et al. “One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.” J Clin Oncol, vol. 26, pp. 3063-3072, 2008.
[7] L. Bodei, M. Cremonesi, C. Grana, P. Rocca, M. Bartolomei, M. Chinol, and G. Paganelli, “Receptor radionuclide therapy with 90Y-(DOTA)0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.” Eur J Nucl Med Mol Imaging, vol. 31, pp. 1038-1046, 2004.
[8] J. Kwekkeboom, J. Mueller-Brand, G. Paganelli, L. B. Anthony, S. Pauwels, L. K. Kvols, T. M. O'dorisio, R. Valkema, L. Bodei , M. Chinol, H. R. Maecke and E. P. Krenning . “Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.” J Nucl Med, vol. 46, pp. 62-66, 2005.
[9] G. Harris, “Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.” Gut, vol. 35, pp. 1-4, 1994.
[10] Wehrmann, S. Senftleben, C. Zachert, D. Müller and R. P. Baum, “Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.” Cancer Biother Radiopharm, vol. 22, pp. 406-416, 2007.
[11] J. Kwekkeboom, W. H. Bakker, J. J. M. Teunissen, et al. “Treatment with Lu-177- DOTA-Tyr3-octreotate in patients with neuroendocrine tumors: interim results (abstract). ”Eur J Nucl Med Mol Imaging, vol. 30, pp. 231, 2003.
[12] Otte, R. Herrmann, A. Heppeler, M. Behe, E. Jermann, P. Powell, H. R. Maecke and J. Muller, “Yttrium-90 DOTATOC: first clinical results.” Eur J Nucl Med, vol.26, pp. 1439 –1447, 1999.
[13] H. Yousefnia, M. Mousavi-Daramoroudi, S. Zolghadri and F. Abbasi-Davani, “Preparation and biodistribution assessment of low specific activity 177Lu-DOTATOC for optimization studies.” Iran J Nucl Med, vol. 24, pp. 85-91, 2016.
[14] K. Bogen, “Simulation software for the Macintosh.” Science, vol. 246, pp. 138-142, 1989.
[15] M. Foster and R. C. Boston, The use of computers in compartmental analysis: the SAAM and CONSAM programs. Boca Raton: USA, 1983, pp. 73-142.
[16] J. A. Jacquez, “Compartmental analysis in biology and medicine.” Ann Arbor: University of Michigan Press, pp. 277–310, 1985.
[17] H. Anderson, “Compartmental modeling and tracer kinetics.” New York: Springer-Verlag, pp. 302, 1983.
[18] R. E. Carson, “Tracer kinetic modeling in PET.” in Positron emission tomography: basic sciences, 2nd ed. D. L. Bailey, D. W. Townsend, P. E. Valk, M. N. Maisey, Eds. London, UK: Springer, 2005, pp. 127–159.
[19] M. L. Ralston, R. I. Jennrich, P. F. Sampson, et al. Fitting pharmacokinetic models with BMDPAR, BMDP technical report no. 58. Los Angeles: UCLA Health Sciences Computing Facilities, 1979.
[20] J. A. Siegel, S. R. Thomas, J. B. Stubbs, M. G. Stabin, M. T. Hays, K. F. Koral, J. S. Robertson, R. W. Howell, B. W. Wessels, D. R. Fisher, D. A. Weber and A. B. Brill, “MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates.” J Nucl Med, vol. 40, pp. 37-61, 1999.
[21] Jalilian, S. Shanehsazzadeh, M. Akhlaghi, J. Garoosi, S. Rajabifar and M. Tavakoli, “Preparation and evaluation of (67Ga)-DTPA-β-1–24-corticotrophin in normal rats.” Radiochim Acta, vol. 96, pp. 435-439, 2008.
[22] Anderson, Compartmental modeling and tracer kinetics. Berlin: Springer-Verlag, 1983.
[23] J. A. Jacquez, Compartmental analysis in biology and medicine. Amsterdam, Holland: Elsevier/North, 1972.